Jonathan Anderman
General Counsel bei COMPASS THERAPEUTICS, INC.
Profil
Jonathan Anderman is currently the Secretary, Vice President & Head-Legal at Compass Therapeutics, Inc. Prior to this, he worked as the Global Commercial Counsel at Biogen, Inc. from 2020 to 2021 and as the Assistant General Counsel at Intarcia Therapeutics, Inc. from 2015 to 2018.
Anderman received his undergraduate degree from The Pennsylvania State University and his graduate degree from Boston University School of Law.
Aktive Positionen von Jonathan Anderman
| Unternehmen | Position | Beginn |
|---|---|---|
| COMPASS THERAPEUTICS, INC. | General Counsel | 01.08.2021 |
Ehemalige bekannte Positionen von Jonathan Anderman
| Unternehmen | Position | Ende |
|---|---|---|
| BIOGEN INC. | Corporate Officer/Principal | 01.08.2021 |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Corporate Officer/Principal | 01.08.2018 |
Ausbildung von Jonathan Anderman
| Boston University School of Law | Graduate Degree |
| The Pennsylvania State University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| COMPASS THERAPEUTICS, INC. | Health Technology |
| BIOGEN INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
